Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer INDNov 12Quarterly updateAkari Therapeutics PlcAtrium Therapeutics
TuHURA Biosciences draws $1.5 million more on Parkview credit facilityNov 6FinancingKintara Therapeutics, Inc.
TuHURA Biosciences draws $650,000 more under Parkview credit lineOct 16FinancingKintara Therapeutics, Inc.
TuHURA draws two more tranches on Parkview credit line, each for $650,000Sep 24FinancingKintara Therapeutics, Inc.
TuHURA Biosciences adopts inducement equity plan, adds detail in amended filingSep 17PeopleKintara Therapeutics, Inc.
TuHURA Biosciences draws $1.5 million more from Parkview credit lineSep 4FinancingKintara Therapeutics, Inc.
TuHURA draws two more tranches on $50 million Parkview credit lineAug 21FinancingKintara Therapeutics, Inc.
TuHURA reports Q2 2026 results, outlines second-half milestones for AML and MCC programsAug 14Quarterly updateKintara Therapeutics, Inc.
TuHURA Biosciences draws $1.5 million more under Parkview credit facilityJul 29FinancingKintara Therapeutics, Inc.
TuHURA Biosciences draws $1.9 million more under Parkview credit lineJul 7FinancingKintara Therapeutics, Inc.